EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir

Bu-Fan Yao, Yang Yang, Shan-Sen Xu, Bo-Hao Tang, Jia Chen, Zi-Jia Guo, Hong-Lin Hu, Wei Zhang, Shu-Meng Fu, Xin-Fang Zhang, Guo-Xiang Hao iD, Xin-Mei Yang und 6 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00614-25 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Bu-Fan Yao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Me…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Drug Development. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Taishan Scholar Program of Shandong Province, Distinguished Young and Middle-aged Scholar of Shandong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During a Public Health Emergency of International Concern (PHEIC), rapid drug development is critical, but traditional clinical trials are time-consuming and high-risk. This study used coronavirus disease 2019 (COVID-19) as an example to highlight the pivotal role of model-informed drug development (MIDD) in expediting the marketing authorization of simnotrelvir in China, a 3CL pro inhibitor for COVID-19 treatment. Three simnotrelvir clinical trials (Phase Ia, Ib, II/III) were optimized using the MIDD approach. Pharmacokinetics was investigated using nonlinear mixed-effects models, exposure was calculated through Monte Carlo simulation and Bayes estimation, and exposure-efficacy/safety relationships were analyzed using linear/logistic regression models. The MIDD approach began with a translational study to predict patients’ starting doses using first-in-human data, preclinical data, and pharmacodynamic surrogate marker. A dose level of 750 mg/100 mg simnotrelvir/ritonavir was recommended, using simulation results with 90.6% of participants’ trough concentration exceeding EC 90 for anti-Omicron variant. Then, a biomarker confirmation study to investigate dose-exposure-response relationship found that 750 mg suppressed viral load more than 300 mg (−4.995 vs. −4.236 log 10 copies/mL, P = 0.0367) in Phase Ib. Finally, a randomized controlled trial to confirm benefit-risk ratio found that simnotrelvir/ritonavir reduced time to sustained resolution of 11 clinical syndromes by 1.5 days compared with placebo, had no serious adverse events, and had a flat exposure-response relationship with viral load reduction, time to sustained resolution, and ≥2 grade treatment-emergent adverse event rate with approved dosage. MIDD enhanced clinical trial success, optimized the benefit-risk profile, and expedited marketing authorization for new drug development in response to PHEIC. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT05339646 , NCT05369676 , and NCT05506176 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentDrug DevelopmentHumansChinaCOVID-19Monte Carlo MethodRitonavirSARS-CoV-2

Stichwörter der Autor:innen

Omicron variantexposure-response analysismodel-informed drug developmentnonlinear mixed-effects modelpublic health emergencysimnotrelvir

Substanzen

Antiviral AgentsRitonavir

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
  • Simcere Zaiming Pharmaceutical Co., Ltd., Nanjing, China.
  • Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, China.
  • Department of Clinical Pharmacy, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, The First Affiliated Hospital of Sha…

ORCID-Profile: Guo-Xiang Hao, Wei Zhao

Förderung

  • National Key R&D Program of China
  • Taishan Scholar Program of Shandong Province
  • Distinguished Young and Middle-aged Scholar of Shandong University
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Yao, B. F., Yang, Y., Xu, S. S., Tang, B. H., Chen, J., Guo, Z. J., Hu, H. L., Zhang, W., Fu, S. M., Zhang, X. F., Hao, G. X., Yang, X. M., Song, L. L., Ye, P. P., Liu, L., Zhu, S. W., Zheng, Y., & Zhao, W. (2025). Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00614-25

Vancouver

Yao BF, Yang Y, Xu SS, Tang BH, Chen J, Guo ZJ, et al. Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00614-25

BibTeX
@article{Yao2025,
  author = {Yao, Bu-Fan and Yang, Yang and Xu, Shan-Sen and Tang, Bo-Hao and Chen, Jia and Guo, Zi-Jia and Hu, Hong-Lin and Zhang, Wei and Fu, Shu-Meng and Zhang, Xin-Fang and Hao, Guo-Xiang and Yang, Xin-Mei and Song, Lin-Lin and Ye, Pan-Pan and Liu, Lian and Zhu, Shun-Wei and Zheng, Yi and Zhao, Wei},
  title = {Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00614-25}
}
Kostenlos starten →